Roche's broad oncology therapy portfolio and diagnostic testing expertise make it a natural sponsor for histology-independent basket trials. It is following the VE-BASKET trial of Zelboraf (vemurafenib) for non-melanoma BRAF V600-mutated cancers with "My Pathway," a basket trial to identify potential new uses for four of its marketed targeted therapies.
VE-BASKET found signals of efficacy in only two of the 10 cohorts studied, non-small cell lung cancer and Erdheim-Chester disease/Langerhans'-cell histiocytosis (see below)